RxDoctor Payments Data

Elaine Boyle

Physician Assistant · Flint, MINPI 1669499281

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 89 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$389
  • Alkermes, Inc.$308
  • Teva Pharmaceuticals USA, Inc.$214
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$140
  • Otsuka America Pharmaceutical, Inc.$105
  • GSK$102
  • plus $502 from 10 others

What the payments were for

  • Food & beverage$1,65594%
  • Education$1066%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,760 in reported general payments places this provider in the 80th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$9,310
Medicare patients
40
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$180,725
TrulicityDulaglutide77$75,372
VraylarCariprazine Hcl44$60,558
JardianceEmpagliflozin59$53,047
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,911
FarxigaDapagliflozin Propanediol32$17,914
MounjaroTirzepatide15$15,663
EliquisApixaban18$12,278
TrintellixVortioxetine Hydrobromide14$10,266
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,839
MyrbetriqMirabegron17$7,748
Spiriva RespimatTiotropium Bromide12$6,564
XareltoRivaroxaban12$6,483
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,754
Atorvastatin Calcium321$3,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$214$180,72513 claims
Lilly USA, LLCTrulicity, Mounjaro$48$91,03592 claims
AbbVieVraylar$389$60,55844 claims
GSKTrelegy Ellipta$102$28,91135 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$10,26614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →